These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


244 related items for PubMed ID: 15147461

  • 1. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
    Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, Dobosz B, Stelmasiak Z.
    Acta Neurol Scand; 2004 Jun; 109(6):390-2. PubMed ID: 15147461
    [Abstract] [Full Text] [Related]

  • 2. CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone.
    Szczuciński A, Kalinowska A, Losy J.
    Eur Neurol; 2007 Jun; 58(4):228-32. PubMed ID: 17827967
    [Abstract] [Full Text] [Related]

  • 3. The effect of cladribine on some parameters of blood and cerebrospinal fluid in patients with relapsing-remitting multiple sclerosis (RR-MS).
    Stelmasiak Z, Bartosik-Psujek H, Belniak-Legieć E, Mitosek-Szewczyk K.
    Ann Univ Mariae Curie Sklodowska Med; 2000 Jun; 55():221-5. PubMed ID: 11482077
    [No Abstract] [Full Text] [Related]

  • 4. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
    Janiec K, Wajgt A, Kondera-Anasz Z.
    Med Sci Monit; 2001 Jun; 7(1):93-8. PubMed ID: 11208501
    [Abstract] [Full Text] [Related]

  • 5. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid.
    Mellergård J, Edström M, Vrethem M, Ernerudh J, Dahle C.
    Mult Scler; 2010 Feb; 16(2):208-17. PubMed ID: 20007431
    [Abstract] [Full Text] [Related]

  • 6. Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis.
    Moreira MA, Tilbery CP, Monteiro LP, Teixeira MM, Teixeira AL.
    Acta Neurol Scand; 2006 Aug; 114(2):109-13. PubMed ID: 16867033
    [Abstract] [Full Text] [Related]

  • 7. The levels of C3 and C4 components of the complement in the sera of relapsing-remitting multiple sclerosis patients (RR-MS) treated by 2-CDA (cladribine).
    Bartosik-Psujek H, Stelmasiak Z, Mitosek-Szewczyk K, Belniak-Legieć E, Dobosz B.
    Ann Univ Mariae Curie Sklodowska Med; 2000 Aug; 55():231-4. PubMed ID: 11482079
    [No Abstract] [Full Text] [Related]

  • 8. CCL5, CXCL10 and CXCL11 chemokines in patients with active and stable relapsing-remitting multiple sclerosis.
    Szczuciński A, Losy J.
    Neuroimmunomodulation; 2011 Aug; 18(1):67-72. PubMed ID: 20720435
    [Abstract] [Full Text] [Related]

  • 9. RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis.
    Rentzos M, Nikolaou C, Rombos A, Boufidou F, Zoga M, Dimitrakopoulos A, Tsoutsou A, Vassilopoulos D.
    Amyotroph Lateral Scler; 2007 Oct; 8(5):283-7. PubMed ID: 17852013
    [Abstract] [Full Text] [Related]

  • 10. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ, CLARITY Study Group.
    Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
    [Abstract] [Full Text] [Related]

  • 11. Effect of cladribine treatment on beta-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis.
    Niezgoda A, Losy J, Mehta PD.
    Folia Morphol (Warsz); 2001 Aug; 60(3):225-8. PubMed ID: 11552664
    [Abstract] [Full Text] [Related]

  • 12. Effect of treatment with methylprednisolone on the serum levels of IL-12, IL-10 and CCL2 chemokine in patients with multiple sclerosis in relapse.
    Rentzos M, Nikolaou C, Rombos A, Evangelopoulos ME, Kararizou E, Koutsis G, Zoga M, Dimitrakopoulos A, Tsoutsou A, Sfangos C.
    Clin Neurol Neurosurg; 2008 Dec; 110(10):992-6. PubMed ID: 18657352
    [Abstract] [Full Text] [Related]

  • 13. Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study.
    Stelmasiak Z, Solski J, Nowicki J, Jakubowska B, Ryba M, Grieb P.
    Mult Scler; 2009 Jun; 15(6):767-70. PubMed ID: 19482866
    [Abstract] [Full Text] [Related]

  • 14. Cladribine: mode of action and implications for treatment of multiple sclerosis.
    Leist TP, Weissert R.
    Clin Neuropharmacol; 2011 Jun; 34(1):28-35. PubMed ID: 21242742
    [Abstract] [Full Text] [Related]

  • 15. Steroid therapy altered serum levels of CCL2 and CCL5 chemokines in multiple sclerosis patients during relapse.
    Bartosik-Psujek H, Stelmasiak Z.
    Eur Neurol; 2004 Jun; 52(4):237-41. PubMed ID: 15550762
    [Abstract] [Full Text] [Related]

  • 16. [The effect of cladribine treatment on beta-2 microglobin in the cerebrospinal fluid and serum of patients with multiple sclerosis].
    Niezgoda A, Losy J.
    Neurol Neurochir Pol; 2000 Jun; 34(2):281-7. PubMed ID: 10962721
    [Abstract] [Full Text] [Related]

  • 17. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC.
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [Abstract] [Full Text] [Related]

  • 18. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu Z, Altunayoglu V.
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [Abstract] [Full Text] [Related]

  • 19. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG.
    Neurology; 2007 Aug 21; 69(8):785-9. PubMed ID: 17709711
    [Abstract] [Full Text] [Related]

  • 20. Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
    Lutterotti A, Kuenz B, Gredler V, Khalil M, Ehling R, Gneiss C, Egg R, Deisenhammer F, Berger T, Reindl M.
    J Neuroimmunol; 2006 Dec 21; 181(1-2):145-9. PubMed ID: 17046070
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 13.